Analytical Data
-
Gene name
HLA-A*33:03&B2M&EGFR(HVKITDFGR) Monomer
- Application
-
Alternative Names
HLA-A*3303 & B2M & EGFR(HVKITDFGR)
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAA79865.1 (G25-T305)&P61769
-
Expression Region
AAA79865.1 (G25-T305)&P61769 (I21-M119)&HVKITDFGR
-
Molecular Weight
40-43 kDa and 13 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of HLA-A*33:03, a specific human leukocyte antigen (HLA) class I molecule, is critical for understanding immune response and disease association, particularly in the context of autoimmune disorders and transplant compatibility. HLA molecules present peptides to CD8+ T cells, enabling immune surveillance. The focus on the HLA-A*33:03 variant, along with its beta-2-microglobulin (B2M) component and the epidermal growth factor receptor (EGFR) peptide HVKITDFGR, offers insights into peptide-binding characteristics and T cell recognition. Recombinant protein production of the HLA-A*33:03-B2M-EGFR complex facilitates structural studies and functional assays to elucidate the implications of this specific HLA variant in oncogenic processes. By investigating the interactions between this monomeric protein and its potential T cell targets, researchers can enhance the understanding of tumor immunology and contribute to the development of immunotherapies that leverage HLA-A*33:03 for targeted treatments in cancers expressing EGFR. This lines up with the increasing relevance of tailored immunotherapy, particularly in cancers where HLA-A*33:03 plays a role, thereby providing important data for clinical applications.
